Jack A. Khattar is the founder of our company and has served as our President, Chief Executive Officer (CEO), and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions as a Board member, President, and CEO of Shire Laboratories, Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s Executive Committee. Prior to that, Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc., a drug delivery company, where he was also responsible for business development, corporate alliances, and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. Mr. Khattar served on the Board of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately held development stage biotechnology company, and is also Chairman of the Board of scPharmaceuticals, a publicly traded biotechnology company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.
What is Jack A. Khattar's net worth?
The estimated net worth of Jack A. Khattar is at least $54.42 million as of October 9th, 2025. Mr. Khattar owns 1,206,578 shares of Supernus Pharmaceuticals stock worth more than $54,416,668 as of December 4th. This net worth estimate does not reflect any other assets that Mr. Khattar may own. Additionally, Mr. Khattar receives an annual salary of $1,630,000.00 as President and Chief Executive Officer, Director at Supernus Pharmaceuticals. Learn More about Jack A. Khattar's net worth.
How old is Jack A. Khattar?
What is Jack A. Khattar's salary?
How do I contact Jack A. Khattar?
Has Jack A. Khattar been buying or selling shares of Supernus Pharmaceuticals?
During the last ninety days, Jack A. Khattar has sold $3,029,143.00 in shares of Supernus Pharmaceuticals stock. Most recently, Jack A. Khattar sold 59,900 shares of the business's stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $50.57, for a transaction totalling $3,029,143.00. Following the completion of the sale, the chief executive officer now directly owns 1,206,578 shares of the company's stock, valued at $61,016,649.46. Learn More on Jack A. Khattar's trading history.
Who are Supernus Pharmaceuticals' active insiders?
Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?
In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company.
Learn More about insider trades at Supernus Pharmaceuticals. Information on this page was last updated on 10/9/2025.
